1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NCI SBIR Phase IIB Bridge Award is sponsored by National Cancer Institute (NCI). The NCI SBIR Phase IIB Bridge Award supports the next stage of development for federally funded Phase II projects, moving them toward commercialization. It is designed to accelerate late-stage clinical development of technologies addressing pediatric and rare cancers.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NCI SBIR Phase IIB Bridge Award Jonathan Franca-Koh, Ph. D. , M.
B. A. Contact Jonathan Franca-Koh to learn more about this program.
Notice Number: RFA-CA-24-022 The application period is closed. Please check back later. View a recording of the informational webinar.
The NCI SBIR Phase IIB Bridge Award supports the next stage of development for federally funded SBIR Phase II projects in the areas of cancer therapeutics, imaging technologies, interventional devices, diagnostics, and prognostics.
With this award, we aim to address the funding gap, known as the “valley of death,” between the end of the SBIR Phase II award and the subsequent round of financing needed to advance a product or service toward commercialization.
To achieve this goal, the Bridge Award funding opportunity is specifically designed to incentivize partnerships between federally funded SBIR Phase II awardees and third-party investors and/or strategic partners. For any single year of the project period, applicants can request a budget of up to $2. 25 million in total costs.
The combined budget requested for the entire project period must not exceed $4. 5 million in total costs. The application must represent a continuation of the research and development efforts performed under a previous federally funded SBIR or STTR Phase II award nearing completion or recently ended.
Development efforts must address one of the following technical/scientific areas: Cancer therapeutics and preventive agents Cancer imaging technologies, interventional devices, and in vivo diagnostics In vitro and ex vivo cancer diagnostics and prognostics Technologies for cancer prevention and control, supportive care, and survivorship Tools and model systems for cancer research For more information on eligibility, please refer to Section TBD of the solicitation.
Third-Party Funding Requirement Competitive preference and funding priority is given to applications deemed likely to result in a commercial product, as indicated by the applicant's ability to secure substantial independent third-party investor funds (i.e., third-party funds that equal or exceed the requested NCI funds).
Examples of third-party investors include, but are not limited to, another company, a venture capital firm, an angel investor, a foundation, a university, a research institution, a state or local government, or any combination of the above.
Applicants must provide a commercialization plan that describes the long-term commercialization strategy and details any independent third-party investor funding that has already been secured or will be provided during the Bridge Award project period.
According to the current listing, eligibility includes: Small businesses with federally funded Phase II SBIR/STTR projects. Confirm the full requirements in the official notice before applying.
The most recent published deadline was September 8, 2026, which has passed. This is an annual program, so a new cycle should follow. Check the funder's website for the next application window.
NCI SBIR Phase IIB Bridge Award is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article